Details of the Drug Reposition

General Information of This Drug (ID: DM7Q98D)

Drug Name
Ruxolitinib   DM7Q98D
Synonyms Ruxolitinib (JAK inhibitor)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
High-risk myelofibrosis DIS8PVZ0 2A20.2 Approved [1]
Essential thrombocythemia DISWWK11 3B63.1Z Approved [2]
------------------------------------------------------------------------------------
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pancreatic cancer DISJC981 2C10 Phase 3 [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 3 [3]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atopic dermatitis DISTCP41 EA80 Phase 1/2 [4]
Vitiligo DISR05SL ED63.0 Phase 1/2 [4]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)